Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIlogy-4: Phase 3 randomized study of JNJ-79635322 versus teclistamab in relapsed or refractory multiple myeloma
CTR20261742Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ramantamig in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
ramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20261742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261742.